• 10:00 am – 10:10 am: Photobiomodulation for Age-Related Macular Degeneration: Outcomes of the LIGHTSITE III Study (First Time for Results to Be Presented) (Diana V. Do, MD)

• 10:10 am – 10:20 am: Update on Pegcetacoplan for Geographic Atrophy: The DERBY and OAKS Phase 3 Trials (David Boyer, MD)

• 10:20 am – 10:30 am: Treatment Response to Avacincaptad Pegol by Patient Baseline Characteristics: A Prespecified Subgroup Analysis of the Phase 3 GATHER2 Study (Michael Ip, MD)

• 10:30 am – 10:40 am: Update on Faricimab for AMD and DME (Diana V. Do, MD)

• 10:40 am – 10:50 am: Hi-Dose Aflibercept for DME: The PHOTON Study (David Boyer, MD)

• 10:50 am – 11:00 am: The HORNBILL Study: A Phase I/IIa Trial Examining BI-X in Patients with Diabetic Macular Ischemia  (Sobha Sivaprasad, MBBS, MS, DM, FRCS, FRCOphth)

• 11:00 am – 11:10 am: Are Biosimilars the Bio-Same? (Rajiv Shah, MD)

• 11:10 am – 11:20 am: Intraocular Inflammation in the Setting of Ocular Gene Therapy: Management and Pearls (David Almeida, MD, MBA, PhD)

• 11:20 am – 11:30 am: Panel Discussion: Managing Retinal Vascular Diseases with Protean Therapeutic Options

                                           Moderator: Diana V. Do, MD

                                           Panelists: Rajat Agrawal, MD, MS, David Almeida, MD, David Boyer, MD, Michael Ip, MD, Rajiv Shah, MD, Sobha Sivaprasad, MBBS, MS, DM, FRCS, FRCOphth